Moleculin(MBRX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Positive outcome from End of Phase 1B/2 Meeting with FDA - Company proceeding with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of R/R AML - Webcast replay of the Company's recent MIRACLE trial update available here HOUSTON, August 14, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nas ...